Cargando…
Brentuximab vedotin in the treatment of a patient with refractory Hodgkin disease and Proteus syndrome – a case report and discussion
Treatment of patients with refractory Hodgkin lymphoma is a significant issue. We report a patient with Proteus syndrome and relapsed Hodgkin lymphoma, whose remission was finally achieved after brentuximab vedotin therapy, allowing her to receive a haploidentical stem cell transplant. The possible...
Autores principales: | Myakova, Natalia, Smirnova, Nadezhda, Evstratov, Dmitry, Abugova, Yulia, Balashov, Dmitry, Diakonova, Yulia, Konovalov, Dmitry, Skvortsova, Yulia, Maschan, Alexey |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
John Wiley & Sons, Ltd
2015
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4527816/ https://www.ncbi.nlm.nih.gov/pubmed/26273462 http://dx.doi.org/10.1002/ccr3.297 |
Ejemplares similares
-
Brentuximab vedotin for relapsed or refractory Hodgkin’s lymphoma
por: Chen, Runzhe, et al.
Publicado: (2015) -
Brentuximab Vedotin Treatment for Primary Refractory Hodgkin Lymphoma
por: Wu, Hung-Bo, et al.
Publicado: (2013) -
Role of brentuximab vedotin in the treatment of relapsed or refractory Hodgkin lymphoma
por: Siddiqi, Tanya, et al.
Publicado: (2014) -
Brentuximab vedotin for relapsed or refractory Hodgkin lymphoma: experience in Turkey
por: Salihoglu, A., et al.
Publicado: (2014) -
Brentuximab vedotin in relapsed/refractory Hodgkin lymphoma. The Hellenic experience
por: Angelopoulou, Maria K., et al.
Publicado: (2017)